Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2019 second-quarter earnings
FINAL LEDE- What You Need to Know About Johnson & Johnson's 2019 Second-Quarter Earnings-Q2 2019 earnings

What you need to know about Johnson & Johnson’s 2019 second-quarter earnings

Check out this infographic breakdown of the company’s second-quarter 2019 performance, with key highlights from its consumer, pharmaceutical and medical devices businesses.

Inset - Quarterly Earnings Ribbon

This morning, Johnson & Johnson shared its second-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 135,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Our solid second-quarter results can be attributed to the dedication and hard work of our Johnson & Johnson colleagues around the world, who perpetually strive to bring differentiated healthcare solutions to the most pressing unmet medical needs,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “As we remain focused on delivering value to all of our stakeholders, we will continue to optimize our portfolio to ensure we make progress against our long-term strategies. Our results during the first half of this year reaffirm our confidence in our 2019 outlook, and position us well to invest for continued success in the future.”

For more details about the company’s second-quarter 2019 results, and to read a comment from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic that highlights key stats.


2019 Q2 Earnings infographic

Johnson & Johnson’s 2019 2nd-Quarter Earnings

Read the earnings press release, which includes full financial details for the second quarter of the year.

Want to see more company earnings information? Find several years of Johnson & Johnson’s quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.